This pilot clinical trial studies protein-sparing modified fast (PSMF) intervention for weight loss in obese endometrial cancer survivors. The PSMF is a diet that is very low in carbohydrates and calories, designed to induce fast, safe weight loss. The diet consists of only lean meats (beef, pork, poultry, and seafood) in amounts adequate to meet protein requirements based on the individual's body weight. The PSMF may help endometrial cancer survivors achieve significant weight loss, reduce the risk of chronic disease, and improve quality of life.
PRIMARY OBJECTIVES: I. Investigate whether the PSMF leads to significant weight loss in obese endometrial cancer survivors (ECS). II. To assess whether the approach is feasible, whether participants will remain in the study for the duration of the intervention while adhering to the various components of the protocol. To assess feasibility, examine the following variables: drop-out rates; rates of adherence to diet and supplemental protocol; and rates of common side-effects. III. Assess whether the PSMF improves biomarkers of disease risk in this population. To assess whether this objective has been met, assess the following variables: blood lipids (total cholesterol, low density lipid \[LDL\] cholesterol, high density lipid \[HDL\] cholesterol, and triglycerides); glucose; and markers of inflammation (C-reactive protein, interleukin-6, tumor necrosis factor \[TNF\]-alpha, and leptin). IV. Assess whether the PSMF leads to improvement in quality of life related to weight loss. OUTLINE: PSMF: Participants are instructed by a registered dietitian (RD) to consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight. The protein recommendation will be communicated to participants in terms of grams per day. Participants are encouraged to adhere as closely as possible to the protein recommendation. Based on the protein recommendation, participants are advised to consume a given amount (in ounces) of beef, pork, poultry and seafood daily, assuming that each ounce of these products contains seven grams of protein. Participants are provided with a digital kitchen scale to weigh protein-containing foods and are permitted up to 2 servings of non-starchy vegetables per day. Participants remain on the PSMF until they have successfully reduced their initial body weight by 15% or up to 6 months. Participants are also provided with supplements to consume daily. WEIGHT MAINTENANCE DIET: After successful weight loss of at least 15% of initial body weight, participants are instructed by a RD to consume a weight maintenance diet or they may remain on the PSMF. The weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the PSMF and consumption of non-starchy vegetables is unlimited. Participants receive handouts that list common foods and the number of carbohydrates in each serving and educated on nutrition label reading for carbohydrates, with emphasis on serving size and total number of carbohydrates per serving. After completion of study, participants are followed up at 2 and 4 weeks and then at 2, 3, 4, 5, and 6 months.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
11
Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
Receive carbohydrate reintroduction handout
Receive education on nutrition label reading for carbohydrates
weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
MetroHealth Medical Center
Cleveland, Ohio, United States
Mean Weight loss assessed with the digital scale
Mean weight loss will be presented as mean total weight loss in kilograms from baseline
Time frame: Baseline up to 6 months
Mean Weight loss assessed with the digital scale
Mean Weight loss will be presented as mean total weight loss in kilograms from baseline.
Time frame: Baseline up to 12 months
Changes in levels of total cholesterol
Average differences in total cholesterol between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value \< 0.05.
Time frame: Baseline up to 6 months
Changes in levels of markers of inflammation (C-reactive protein)
Average differences in C-reactive protein between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value \< 0.05.
Time frame: Up to 6 months
Changes in levels of glucose
Differences in glucose levels between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value \< 0.05.
Time frame: Up to 6 months
Number of drop-out participants
Presented as the difference in the number of participants who completed the study from the number of participants enrolled at baseline. This is reported as one of the markers of feasibility.
Time frame: Up to 6 months
Average percentage of positive urinary ketone tests as a marker of dietary adherence
Assessed using the presence of urinary ketones beginning on day four of the intervention. Adherence rates will be presented as the percentage of positive urinary ketone tests for the duration of the intervention.
Time frame: Up to 6 months
Number of Participant with reported side effects
Adverse events will be recorded by participants on a daily basis. Number of participants with related adverse events will be reported as one of the measures of feasibility
Time frame: Up to 6 months
Changes in quality-of-life as assessed by the Obesity and Weight Loss Quality-of-Life Questionnaire
The difference between mean quality of life scores at the two time points will be assessed using a one-sided anova test with statistical significance set at p \< 0.05.
Time frame: Baseline up to 6 months
Changes in levels of markers of inflammation (interleukin 6)
Average differences in interleukin 6 between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value \< 0.05.
Time frame: Up to 6 months
Changes in levels of markers of inflammation (tumor necrosis factor - alpha)
Average differences in tumor necrosis factor - alpha between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value \< 0.05.
Time frame: Up to 6 months
Changes in levels of markers of inflammation (leptin)
Average differences of leptin between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value \< 0.05.
Time frame: Up to 6 months
Changes in levels of LDL-cholesterol
Average differences between time points for LDL-cholesterol will be assessed using a one-sided anova test with statistical significance defined as having a p-value \< 0.05.
Time frame: Baseline up to 6 months
Changes in levels of HDL-cholesterol
Average differences between time points for HDL-cholesterol will be assessed using a one-sided anova test with statistical significance defined as having a p-value \< 0.05.
Time frame: Baseline up to 6 months
Changes in levels of triglycerides
Average differences between time points for triglycerides will be assessed using a one-sided anova test with statistical significance defined as having a p-value \< 0.05.
Time frame: Baseline up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.